Delisting risk
Curanex Pharmaceuticals (CURX)
Develops a botanical drug candidate for ulcerative colitis and inflammatory diseases.
$4.55
At close+0.05 (+1.11%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 3 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 3 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −3 | −3 | −3 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −3 | −3 | −3 |
| Net income from continuing operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −3 | −3 | −3 |
| Net income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −3 | −3 | −3 |
| EPS, basic | −$0.01 | −$0.06 | −$0.03 | −$0.07 | −$0.10 | −$0.10 | −$0.04 | −$0.67 | −$2.17 | −$2.22 | −$2.32 |
| EPS, diluted | −$0.01 | −$0.06 | −$0.03 | −$0.07 | −$0.10 | −$0.10 | −$0.04 | −$0.67 | −$2.17 | −$2.22 | −$2.32 |
| Weighted average shares, basic | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Weighted average shares, diluted | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −3 | −3 | −3 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −3 | −3 | −3 |